InvestorsHub Logo
Followers 76
Posts 10333
Boards Moderated 0
Alias Born 02/23/2010

Re: None

Tuesday, 03/02/2021 12:46:22 PM

Tuesday, March 02, 2021 12:46:22 PM

Post# of 403113
Brilacidin’s ability to disrupt viral integrity suggests Brilacidin likely is not subject to resistance developing due to coronavirus variants—unlike current COVID-19 treatments, such as monoclonal antibodies and convalescent plasma, and first-generation COVID-19 vaccines. This mechanism of action supports Brilacidin as a clearly differentiated antiviral in clinical development.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News